Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)

被引：0
|
作者：
Marye J. Boers-Sonderen
Carla M. L. van Herpen
Winette T. A. van der Graaf
Ingrid M. E. Desar
Mirjam G. W. Arens- van der Logt
Yvo M. de Beer
Petronella B. Ottevanger
Nielka P. van Erp
机构：
[1] Radboud University Medical Centre,Department of Medical Oncology, 452
[2] Maastricht University Medical Centre+,Department of Clinical Pharmacy and Toxicology
[3] Maastricht University,School CAPHRI
[4] Maastricht University,Department of Toxicology
[5] Radboud University Medical Centre,Department of Clinical Pharmacy
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Pegylated liposomal doxorubicin; Pharmacokinetics; Pharmacodynamics; Progression-free survival; Toxicities;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：457 / 463
页数：6
相关论文
共 50 条
  • [41] Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD)
    Sanchez Henarejos, Pilar
    Ros Martinez, Silverio
    Marin Zafra, Gema R.
    Alonso Romero, Jose L.
    Navarrete Montoya, Agustin
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (07): : 486 - 487
  • [42] Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
    Andreopoulou, E.
    Gaiotti, D.
    Kim, E.
    Downey, A.
    Mirchandani, D.
    Hamilton, A.
    Jacobs, Allan
    Curtin, John
    Muggia, F.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 716 - 721
  • [43] Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD)
    Pilar Sánchez Henarejos
    Silverio Ros Martínez
    Gema R. Marín Zafra
    José L. Alonso Romero
    Agustín Navarrete Montoya
    Clinical and Translational Oncology, 2009, 11 : 486 - 487
  • [44] Temozolomide/pegylated liposomal doxorubicin (PLD) in progressive glioblastoma multiforme (GBM)
    Dresemann, G
    NEURO-ONCOLOGY, 2005, 7 (03) : 310 - 310
  • [45] Relationship Between Complement Factors and CC Chemokines and the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Doxorubicin (PLD) in Patients with Refractory Epithelial Ovarian Cancer (EOC)
    Song, G.
    Moore, S.
    Tarrant, T.
    Dobrovolskaia, M.
    Barrow, D.
    Kumar, P.
    Newman, S.
    Bae-Jump, V.
    Gehrig, P.
    Zamboni, W.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 39 - 40
  • [46] A metanalysis of the efficacy and safety of pegylated liposomal doxorubicin
    Castellanos-Toledo, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models
    Gabizon, A
    Tzemach, D
    Mak, L
    Bronstein, M
    Horowitz, AT
    JOURNAL OF DRUG TARGETING, 2002, 10 (07) : 539 - 548
  • [48] Extensive cutaneous postinflammatory Hyperpigmentation as a side effect of Chemotherapy with pegylated liposomal Doxorubicin (Caelyx®)
    Stegemann, T.
    Baur, V.
    Mechlin, A. D.
    Papadopoulos, T.
    Schultz, E. S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 (09): : 774 - 775
  • [49] Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC).
    Ruff, P
    Moodley, SD
    Rapoport, BL
    Chasen, MR
    Jacobs, C
    Hacking, D
    Voroblof, DA
    ANNALS OF ONCOLOGY, 2000, 11 : 69 - 70
  • [50] Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T plus pegylated liposomal doxorubicin (PLD).
    Yver, A.
    Cohen, R.
    Williams, D.
    Von Mehren, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 536S - 536S
12345